Over the Counter Profit Potential
is Huge
May 30, 2019 -- InvestorsHub NewsWire -- via microcapspeculators.com --
According to the National Marketing Institute’s website, nearly 50%
of Americans rely on supplements in their daily lives. There
are more than 80 therapeutic categories of OTC drugs, ranging from
acne drug products to weight control drug products. OTC
medicines and supplements are an accepted and often first-line
therapy and are recommended for many of the most common conditions
and ailments affecting the U.S. population.
One OTC company selling OTC products you should start
researching right away is Innovus Pharmaceuticals,
Inc. (USOTC:
INNV).
INNV markets over 35 products in the United States and in a
range of countries around the world. Its marketed products
include FlutiCare® (the main competitor of Flonase on Amazon),
GlucoGorx®, Zestra®, EjectDelay®,
Sensum+®, Zestra Glide®, Vesele®,
PeVarx®, Diabasens and Androferti®.
Innovus Pharma also offers Beyond
Human® testosterone booster, ketones, krill oil,
omega 3 fish oil, Vision Formula™, blood sugar, colon cleanse,
green coffee extract, and growth agent;
RecalMax® and RecalMax® nitric
oxide strips for brain health; UriVarx®, a supplement
for overall bladder health and ProstaGorx®, a supplement
for prostate support
The company’s strength is its sales platform. For example,
their first product called Vesele had sales of 200 units a
year when they acquired it. INNV was able to increase sales
to close to $3.5M in one year. INNV’s sales and marketing
platform called Beyond Human targeting between 20-30 million
consumers on a monthly basis. With over 35 commercial
products in multiple countries and a unique direct to consumer
sales and marketing platform, the company has been doubling its
revenue for the past three years.
The company just took on Regoxidine™, a topical foam containing
5% minoxidil that is approved by the FDA as a hair regrowth
treatment and is used to grow hair on the top of the scalp.
The active ingredient is 5% minoxidil and is comparable to the
Rogaine line. Using their sales platform, this could be a big
winner.
The companies we’re highlighting today include:
Innovus Pharmaceuticals, Inc. (USOTC:
INNV), OrganiGram Holdings (TSXV:
OGI), Aphria (NYSE:
APHA), The Green Organic Dutchman (TGODF), and Canopy Growth
Corporation (NYSE:
CGC).
Innovus Pharmaceuticals, Inc. (USOTC:
INNV)
(Market Cap:
$5.601M;
Share Price: $2.17), an emerging
commercial-stage pharmaceutical company that delivers safe,
innovative and effective over-the-counter medicine and consumer
care products to improve men’s and women's health and respiratory
diseases, has had quite the start to the year: revenues of
approximately $5.4 million, an increase of $0.8 million
or 18.0% compared to prior year and $0.6 million or 12.8% compared
to the prior quarter. With annual 2019 net revenue projected
to achieve record levels of $26-28 million, INNV is in a good
position.
“We are encouraged by our start to the 2019 year with
revenues increasing 18% and 12.8% in the comparable quarter in
the prior year and the previous quarter, respectively. The Company
has been able to strategically diversify its revenue channels
during the quarter without significant disruption to overall
revenue and achieving revenues from e-commerce platforms by
approximately 30%. Additionally, with twelve products now approved
by Health Canada, we are poised to focus more marketing efforts in
Canada where we have historically experienced superior returns
which we believe will help us achieve our goal of profitability,”
stated Bassam Damaj, President and Chief Executive Officer of
Innovus Pharma.
What investors may be most excited about however, is new CBD
treatment. The company launched
first hemp-derived Cannabidiol product with MZS Sleeping
Aid™. Retailers like Walmart, Target, and Walgreens
are getting in line to sell CBD products. With hemp being
legal through the new Farm Bill, this makes companies like INNV
even more enticing. Start your research today.
________
OrganiGram Holdings (TSXV:
OGI) (Market Cap: $1.192B; Share Price:
$7.69), a leading licensed producer of cannabis,
announced that its common shares will commence trading on the
Nasdaq Global Select Market under the symbol "OGI" on Tuesday May
21, 2019. Organigram's common shares will continue to be
listed and trade on the Toronto Venture Exchange (TSXV), also
under the symbol "OGI".
________
Aphria Inc. (NYSE:
APHA) (Market Cap: $1.764B; Share Price:
$7.00) shares fell after the Canadian cannabis
company reported fiscal third-quarter results. It posted
a C$108.2 million ($81.1 million) loss for its fiscal third
quarter, or 43 cents a share, after a profit of C$12.9
million, or 8 cents a share, in the same period a year ago.
Revenue climbed to C$73.6 million from C$10.3 million in the first
full quarter of Canadian legal cannabis. But the company sold
less cannabis than a year ago—kilograms sold fell to 2,636.5 from
3,408.9, while the average retail selling price for medical
cannabis increased to C$8.03 per gram from C$7.51, primarily
because of higher oil sales.
In April, it announced that the previously announced take-over
bid (the "Offer") by Green Growth Brands Inc. ("GGB") has failed to
meet the statutory minimum tender condition and has now expired and
is terminated. As previously announced on April 15,
2019, the company entered into a definitive agreement with GGB to
accelerate the expiry date of the Offer to April 25, 2019, as well
as to terminate certain arrangements with GA Opportunities Corp.
("GAOC") for consideration of $89.0 million payable on future dates
as set out in the April 15th press release. The Offer is now
expired and terminated and no longer open to any Aphria shareholder
to tender their shares. Accordingly, GGB will not be taking
up any securities that may have been tendered to the Offer.
GGB will promptly return to the securityholder any Aphria shares
tendered and not withdrawn during the period from the commencement
of the Offer up to the expiry time of the Offer.
________
The Green Organic Dutchman (TGODF) (Market Cap:
$782.932M; Share Price: $2.90) recently participated
in Virtual Investor Conferences.
The Green Organic Dutchman is an Ontario, Canada, based marijuana
company that was IPO’d in spring 2018 and is currently valued at
$957 million.
The Green Organic Dutchman expects that its production capacity
will be 170,000 kg marijuana a year, based on several deals that
have expanded the company’s asset base during 2018.
This includes the June 2018 acquisition of a facility
(approximately 280,000 square foot) that The Green Organic Dutchman
plans to use for producing marijuana-containing edible products and
marijuana-infused beverages. It recently announced that
effective March 25th, 2019 sales of certified-organic cannabis have
started with national distribution to medical patients. The
Growers' Circle is a select group of patients across Canada now
receiving TGOD's first certified-organic flower.
________
Canopy Growth Corporation (NYSE:
CGC) (Market Cap: $14.727B; Share Price:
$42.48) signed an offtake agreement with
PharmHouse Inc., a 49 per cent-owned joint venture of Canopy Rivers
Inc. (CNOPOF). Under the terms of the agreement, PharmHouse
has agreed to allocate high quality cannabis flower from an
additional 20 per cent of the flowering space available at
its Leamington greenhouse facility over the next three
years.
Legal Disclaimer:
This article was written by Regal Consulting, LLC (“Regal
Consulting”). Regal Consulting
has agreed to a three-month term consulting agreement with
Innovus Pharmaceuticals, Inc. (INNV) signed 05/20/2019. The
agreement calls for $20,000 in cash and 10,000 restricted 144
shares per month. All payments were made directly by Innovus
Pharmaceuticals, Inc. to Regal Consulting, LLC to provide investor
relations services, of which this article is a part of. Regal
Consulting also paid one thousand dollars cash to
microcapspeculators.com to distribute this article. Regal
Consulting may have a position in the securities mentioned in this
article at the time of publication, and may increase or decrease
its position without notice. This article is based on public
information and the opinions of Regal Consulting. INNV was
given an opportunity to edit this article. This article contains
forward-looking statements that are subject to certain risks and
uncertainties that could cause actual results to differ materially
from any results predicted herein. Regal Consulting is not
registered with any financial or securities regulatory authority,
and does not provide or claim to provide investment advice.
http://www.regalconsultingllc.com/full
legal disclaimer/
Full Legal Disclaimer Click Here.
Contact Information:
Company Name: ACR Communication LLC.
Contact Person: Media Manager
Email: info@microcapspeculators.com
Phone: 1-702-720-6310
Country: United States
SOURCE: microcapspeculators.com
Canopy Growth (NASDAQ:CGC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Canopy Growth (NASDAQ:CGC)
Historical Stock Chart
From Apr 2023 to Apr 2024
